SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001062993-21-000052
Filing Date
2021-01-04
Accepted
2021-01-04 20:11:25
Documents
2
Period of Report
2021-01-01

Document Format Files

Seq Description Document Type Size
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.html 3  
1 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES form3.xml 3 5262
2 EXHIBIT 24 exhibit24-4.htm EX-24.4 7744
  Complete submission text file 0001062993-21-000052.txt   14399
Mailing Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9 (416) 595-0627
Trillium Therapeutics Inc. (Issuer) CIK: 0001616212 (see all company filings)

IRS No.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations

Mailing Address C/O TRILLIUM THERAPEUTICS INC. 2488 DUNWIN DRIVE MISSISSAUGA A6 L5L 1J9
Business Address
Skvarka Jan (Reporting) CIK: 0001838042 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36596 | Film No.: 21503561